ClinicalTrials.gg
CompletedNCT01165177Updated Feb 10, 2021Results posted

Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older

A Phase 3 interventional study of Herpes Zoster Vaccine GSK1437173A and Placebo in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 274 sites in 18 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-10.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
16,165
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.

Enrollment
3rd of 46
16,165 · median 239
Started
2010
with 3 others
Phase 3
22 of 46
2 open now
Registered
4th of 46
by date
Lead sponsor
26 of 46
GlaxoSmithKline

Among the 46 studies testing shingrix in Herpes Zoster, this one is the 3rd largest by enrollment, is one of 4 that started in 2010, is one of 22 in phase 3, and was the 4th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About shingrix

shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing shingrix in Herpes Zoster, or all of them as a file.
02

Study summary

The purpose of this observer-blind study is to evaluate the efficacy, safety and immunogenicity of GSK Biologicals' candidate Herpes Zoster (HZ) vaccine in adults aged ≥ 50 years.

Two studies [ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229)] are being conducted concurrently to evaluate efficacy of GSK1437173A vaccine. A pooled analysis of data from both studies combined will be conducted contingent on each study achieving its objectives. The protocol posting of study ZOSTER-022 also deals with the outcome measures related to the pooled analysis.

Read the detailed description

This protocol summary has been updated following Protocol Amendment 4 changes to study objectives and endpoints and the analyses of the objectives in 2 steps.

Step 1 will include analyses of the following objectives of ZOSTER-006 (NCT01165177): all HZ VE objectives and all reactogenicity/safety and immunogenicity objectives. At step 2, all objectives of study ZOSTER-006 (NCT01165177) will be analyzed. Objectives already analyzed at step 1 will be re-analyzed (confirmatory descriptive in case of inferential analysis at step 1 or descriptive analysis otherwise). At step 2, pooled analyses of studies ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) are planned; overall PHN VE in subjects ≥ 70 YOA, and other pre-specified endpoints will be analyzed.

03

Conditions studied

  • Herpes Zoster

Browse trials for

Keywords

  • subjects 50 years and older
  • vaccine
  • immunogenicity
  • efficacy
  • Herpes Zoster
  • safety
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who the investigator believes will comply with the requirements of the protocol;
  • Written obtained from the subject;
  • A male or female aged 50 years or older at the time of the first vaccination;
  • Female subjects of non- may be enrolled in the study;

For this study population, non-childbearing potential is defined as current tubal ligation, hysterectomy, ovariectomy or .

OR Female subjects of childbearing potential may be enrolled in the study, if the subject has practiced adequate for 30 days prior to vaccination, and has a negative urine pregnancy test on the day of vaccination, and has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series;

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period;
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product;
  • Any confirmed or suspected or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy;
  • History of HZ;
  • Previous vaccination against varicella or HZ;
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. Additionally, consider allergic reactions to other material or equipment related to study participation;
  • Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study;
  • Receipt of immunoglobulins and/or any blood products within the 90 days preceding the first dose of study vaccine or planned administration during the study period;
  • Administration or planned administration of any other immunizations within 30 days before the first or second study vaccination or scheduled within 30 days after study vaccination. However, licensed non-replicating vaccines may be administered up to 8 days prior to each dose and/or at least 14 days after any dose of study vaccine;
  • Any other condition that, in the opinion of the investigator, might interfere with the evaluations required by the study;
  • Acute disease and/or fever at the time of enrollment;
  • Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
  • Pregnant or lactating female;
  • Female planning to become pregnant or planning to discontinue precautions.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
16,165 participants (actual)

Study arms

  • Experimental
    GSK1437173A group

    Subjects will receive Herpes Zoster Vaccine GSK1437173A according to a 0, 2-month schedule

    Biological: Herpes Zoster Vaccine GSK1437173A

  • Placebo comparator
    Placebo group

    Subjects will receive NaCl solution placebo according to a 0, 2-month schedule

    Biological: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Confirmed Herpes Zoster (HZ) Cases

    Confirmed HZ cases during the study were assessed in the Modified Total Vaccinated Cohort (mTVc)

    Time frame: During the entire study period (3 to 5 year period following Day 0)

Secondary outcomes

  1. Number of Subjects With Any Episodes of Post-Herpetic Neuralgia (PHN)

    The incidence of PHN was calculated using the modified total vaccinated chort.

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  2. Number of Subjects With a Reduction of Duration of Severe 'Worst' HZ-associated Pain

    Severe 'worst' pain was defined as HZ-associated pain rated as 3 or above on the 'worst pain' Zoster Brief Pain Inventory (ZBPI) questionnaire. The outcome assessed the duration of severe 'worst' HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period as measured by the ZBPI in subjects with confirmed HZ. This analysis involved any subject reporting clinically significant pain (i.e. pain with a score of 3 or more on a 0-10 point scale) at any time during the study.

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  3. Number of Subjects With Confirmed HZ Episode Related Mortality

    The analysis focused on the number of subjects who died due to HZ

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  4. Number of Subjects With HZ Related Complications

    The analysis focused on the incidence of HZ complications in subjects with confirmed HZ

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  5. Number of Subjects With Confirmed HZ Episode Related Hospitalizations

    The analysis focused on confirmed HZ episode related hospitalizations.

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  6. Number of Subjects With a Confirmed HZ Episode Having a Reduction of Duration of Pain Medication Associated With HZ

    The analysis focused on patients who experienced a reduction in duration of pain medication administered for HZ in subjects with confirmed HZ.

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  7. Number of Subjects With a Confirmed HZ Episode Taking Pain Medication Associated With HZ

    The analysis focused on subjects taking pain medication due to HZ

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  8. Number of Days With Severe 'Worst' HZ-associated Pain.

    Severe 'worst' pain was defined as HZ-associated pain rated as 3 or above on the 'worst pain' ZBPI questionnaire. This Outcome Measure was only assessed participants with confirmed HZ. This analysis involved any subject reporting ZBPI clinically significant pain (i.e. pain with a score of 3 or more on a 0-10 point scale) at any time during the study.

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  9. Number of Subjects With Confirmed HZ Episode Related Mortality and Hospitalizations

    The analysis focused on confirmed HZ episode related hospitalizations and deaths.

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  10. Number of Subjects With HZ Related Complications, by Complication Type

    Complication types included HZ vasculitis, Disseminated Disease, Ophtalmic Disease, Neurologic Disease, Visceral Disease and Stroke. This Outcome Measure was only assessed participants with confirmed HZ.

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  11. Distribution of Pain Medication Associated With HZ

    The distribution of pain medication included 1 to 3 or more separate medications. This Outcome Measure was only assessed on participants with confirmed HZ.

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  12. Number of Days of Pain Medication Associated With HZ

    The analysis was performed on subjects with a confirmed HZ episode

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  13. Number of Subjects With Any and Grade 3 Solicited Local Symptoms

    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = Significant pain at rest that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed.

    Time frame: During the 7-day (Days 0-6) post-vaccination period

  14. Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms

    Assessed solicited general symptoms were fatigue, GI (gastrointestinal) symptoms (included nausea, vomiting, diarrhoea and/or abdominal pain), fever \[defined as oral, axillary, rectal or tympanic temperature equal to or above 37.5 degrees Celsius (°C)\], headache, myalgia, shivering and sweating. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = temperature\> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

    Time frame: Within the 7-day (Days 0-6) post-vaccination period

  15. Number of Subjects With Any and Grade 3 Symptoms (Solicited and Unsolicited)

    Number of subjects with any and grade 3 solicited and unsolicited symptoms were tabulated

    Time frame: Within the 7-day (Days 0-6) post-vaccination period

  16. Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)

    Occurrence and relationship to vaccination of any potential immune-mediated diseases (pIMDs) in all subjects

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  17. Number of Subjects With AEs With Any and Related Medically Attended Visit

    Occurrence and relationship to vaccination of medically attended visits (defined as hospitalizations, emergency room visits or visits to or from medical personnel), other than routine health care visits in all subjects.

    Time frame: From Month 0 to Month 8 post-vaccination

  18. Number of Subjects With Unsolicited Adverse Events (AEs)

    Occurrence, intensity and relationship to vaccination of unsolicited AEs, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification in all subjects An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

    Time frame: Within 30 days (Days 0 - 29) after each vaccination

  19. Number of Subjects With Serious Adverse Events (SAEs)

    Occurrence and relationship to vaccination of all SAEs in all subjects. Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: Within the 30-day (Days 0-29) post-vaccination period, up to Month 14 and up to study end (3 to 5 year period following Day 0)

  20. Number of Subjects With SAEs Related to Study Participation or to a Concurrent GSK Medication/Vaccine

    The number of subjects with SAEs related to study participation or to a concurrent GSK medication/vaccine were tabulated

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  21. Number of Subjects With Fatal SAEs

    Number of subjects with fatal SAEs during the entire study period were tabulated

    Time frame: During the entire study period (3 to 5 years following day 0)

07

Results

Posted May 1, 2017

Participant flow

Participant flow — Overall Study
MilestoneGSK1437173A GroupPlacebo Group
Started76957710
Completed67736808
Not completed922902
Withdrew: Serious adverse event227235
Withdrew: Withdrawal by subject368354
Withdrew: Protocol violation1921
Withdrew: Non-serious adverse event3018
Withdrew: Other unspecified reasons4735
Withdrew: Suspected hz episode02
Withdrew: Lost to follow-up183194
Withdrew: Migrated/ moved from study area4843

Outcome measures

PrimaryNumber of Subjects With Confirmed Herpes Zoster (HZ) Cases

Confirmed HZ cases during the study were assessed in the Modified Total Vaccinated Cohort (mTVc)

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Number of Subjects With Confirmed Herpes Zoster (HZ) Cases
ParticipantsGSK1437173A 50-59 YOA GroupGSK1437173A 60-69 YOA GroupGSK1437173A Over 70 YOA GroupGSK1437173A Overall Ages GroupPlacebo 50-59 YOA GroupPlacebo 60-69 YOA GroupPlacebo Over 70 YOA GroupPlacebo Overall Ages Group
Number of Subjects With Confirmed Herpes Zoster (HZ) Cases3216877548210
Statistical analysis
  • GSK1437173A 50-59 YOA Group vs Placebo 50-59 YOA Group · Poisson exact test · p = <0.0001 (Two sided exact P-value conditional to number of cases.) · Vaccine efficacy: 96.6 · 95% CI 89.6 to 99.3
  • GSK1437173A 60-69 YOA Group vs Placebo 60-69 YOA Group · Poisson exact test · p = <0.0001 (Two sided exact P-value conditional to number of cases.) · Vaccine efficacy: 97.4 · 95% CI 90.1 to 99.7
  • GSK1437173A Over 70 YOA Group vs Placebo Over 70 YOA Group · Poisson exact test · p = 0.0001 (Two sided exact P-value conditional to number of cases.) · Vaccine efficacy: 97.9 · 95% CI 87.9 to 100
  • GSK1437173A Overall Ages Group vs Placebo Overall Ages Group · Poisson exact test · p = <0.0001 (Two sided exact P-value conditional to number of cases.) · Vaccine efficacy: 97.2 · 95% CI 93.7 to 99
SecondaryNumber of Subjects With Any Episodes of Post-Herpetic Neuralgia (PHN)

The incidence of PHN was calculated using the modified total vaccinated chort.

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Number of Subjects With Any Episodes of Post-Herpetic Neuralgia (PHN)
ParticipantsGSK1437173A 50-59 YOA GroupGSK1437173A 60-69 YOA GroupGSK1437173A Over 70 YOA GroupGSK1437173A Overall Ages GroupPlacebo 50-59 YOA GroupPlacebo 60-69 YOA GroupPlacebo Over 70 YOA GroupPlacebo Overall Ages Group
Number of Subjects With Any Episodes of Post-Herpetic Neuralgia (PHN)000082818
Statistical analysis
  • GSK1437173A 50-59 YOA Group vs Placebo 50-59 YOA Group · Poisson exact test · p = 0.0081 · Vaccine efficacy: 100 · 95% CI 40.9 to 100
  • GSK1437173A 60-69 YOA Group vs Placebo 60-69 YOA Group · Poisson exact test · p = 0.5097 · Vaccine efficacy: 100 · 95% CI -442.8 to 100
  • GSK1437173A Over 70 YOA Group vs Placebo Over 70 YOA Group · Poisson exact test · p = 0.0078 · Vaccine efficacy: 100 · 95% CI 41.4 to 100
  • GSK1437173A Overall Ages Group vs Placebo Overall Ages Group · Poisson exact test · p = <0.0001 · Vaccine efficacy: 100 · 95% CI 77.1 to 100
SecondaryNumber of Subjects With a Reduction of Duration of Severe 'Worst' HZ-associated Pain

Severe 'worst' pain was defined as HZ-associated pain rated as 3 or above on the 'worst pain' Zoster Brief Pain Inventory (ZBPI) questionnaire. The outcome assessed the duration of severe 'worst' HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period as measured by the ZBPI in subjects with confirmed HZ. This analysis involved any subject reporting clinically significant pain (i.e. pain with a score of 3 or more on a 0-10 point scale) at any time during the study.

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Number of Subjects With a Reduction of Duration of Severe 'Worst' HZ-associated Pain
ParticipantsGSK1437173A 50-59 YOA GroupGSK1437173A 60-69 YOA GroupGSK1437173A Over 70 YOA GroupGSK1437173A Overall Ages GroupPlacebo 50-59 YOA GroupPlacebo 60-69 YOA GroupPlacebo Over 70 YOA GroupPlacebo Overall Ages Group
Number of Subjects With a Reduction of Duration of Severe 'Worst' HZ-associated Pain4127917456221
SecondaryNumber of Subjects With Confirmed HZ Episode Related Mortality

The analysis focused on the number of subjects who died due to HZ

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Number of Subjects With Confirmed HZ Episode Related Mortality
ParticipantsGSK1437173A 50-59 YOA GroupGSK1437173A 60-69 YOA GroupGSK1437173A Over 70 YOA GroupGSK1437173A Overall Ages GroupPlacebo 50-59 YOA GroupPlacebo 60-69 YOA GroupPlacebo Over 70 YOA GroupPlacebo Overall Ages Group
Number of Subjects With Confirmed HZ Episode Related Mortality00000000
SecondaryNumber of Subjects With HZ Related Complications

The analysis focused on the incidence of HZ complications in subjects with confirmed HZ

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Number of Subjects With HZ Related Complications
ParticipantsGSK1437173A 50-59 YOA GroupGSK1437173A 60-69 YOA GroupGSK1437173A Over 70 YOA GroupGSK1437173A Overall Ages GroupPlacebo 50-59 YOA GroupPlacebo 60-69 YOA GroupPlacebo Over 70 YOA GroupPlacebo Overall Ages Group
Number of Subjects With HZ Related Complications00001326
SecondaryNumber of Subjects With Confirmed HZ Episode Related Hospitalizations

The analysis focused on confirmed HZ episode related hospitalizations.

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Number of Subjects With Confirmed HZ Episode Related Hospitalizations
ParticipantsGSK1437173A 50-59 YOA GroupGSK1437173A 60-69 YOA GroupGSK1437173A Over 70 YOA GroupGSK1437173A Overall Ages GroupPlacebo 50-59 YOA GroupPlacebo 60-69 YOA GroupPlacebo Over 70 YOA GroupPlacebo Overall Ages Group
Number of Subjects With Confirmed HZ Episode Related Hospitalizations00000000
SecondaryNumber of Subjects With a Confirmed HZ Episode Having a Reduction of Duration of Pain Medication Associated With HZ

The analysis focused on patients who experienced a reduction in duration of pain medication administered for HZ in subjects with confirmed HZ.

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Number of Subjects With a Confirmed HZ Episode Having a Reduction of Duration of Pain Medication Associated With HZ
ParticipantsGSK1437173A 50-59 YOA GroupGSK1437173A 60-69 YOA GroupGSK1437173A Over 70 YOA GroupGSK1437173A Overall Ages GroupPlacebo 50-59 YOA GroupPlacebo 60-69 YOA GroupPlacebo Over 70 YOA GroupPlacebo Overall Ages Group
Number of Subjects With a Confirmed HZ Episode Having a Reduction of Duration of Pain Medication Associated With HZ3216826345190
SecondaryNumber of Subjects With a Confirmed HZ Episode Taking Pain Medication Associated With HZ

The analysis focused on subjects taking pain medication due to HZ

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Number of Subjects With a Confirmed HZ Episode Taking Pain Medication Associated With HZ
ParticipantsGSK1437173A 50-59 YOA GroupGSK1437173A 60-69 YOA GroupGSK1437173A Over 70 YOA GroupGSK1437173A Overall Ages GroupPlacebo 50-59 YOA GroupPlacebo 60-69 YOA GroupPlacebo Over 70 YOA GroupPlacebo Overall Ages Group
Number of Subjects With a Confirmed HZ Episode Taking Pain Medication Associated With HZ3216826345190
SecondaryNumber of Days With Severe 'Worst' HZ-associated Pain.

Severe 'worst' pain was defined as HZ-associated pain rated as 3 or above on the 'worst pain' ZBPI questionnaire. This Outcome Measure was only assessed participants with confirmed HZ. This analysis involved any subject reporting ZBPI clinically significant pain (i.e. pain with a score of 3 or more on a 0-10 point scale) at any time during the study.

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Mean · Days
Number of Days With Severe 'Worst' HZ-associated Pain.
DaysGSK1437173A 50-59 YOA GroupGSK1437173A 60-69 YOA GroupGSK1437173A Over 70 YOA GroupGSK1437173A Overall Ages GroupPlacebo 50-59 YOA GroupPlacebo 60-69 YOA GroupPlacebo Over 70 YOA GroupPlacebo Overall Ages Group
Number of Days With Severe 'Worst' HZ-associated Pain.12.0 ± 11.878.0 ± 0.09.0 ± 4.220.6 ± 26.828.7 ± 48.421.6 ± 29.344.0 ± 74.430.2 ± 51.9
SecondaryNumber of Subjects With Confirmed HZ Episode Related Mortality and Hospitalizations

The analysis focused on confirmed HZ episode related hospitalizations and deaths.

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Number of Subjects With Confirmed HZ Episode Related Mortality and Hospitalizations
ParticipantsGSK1437173A 50-59 YOA GroupGSK1437173A 60-69 YOA GroupGSK1437173A Over 70 YOA GroupGSK1437173A Overall Ages GroupPlacebo 50-59 YOA GroupPlacebo 60-69 YOA GroupPlacebo Over 70 YOA GroupPlacebo Overall Ages Group
Mortality00000000
Hospitalization00000000
Mortality or hospitalization00000000
SecondaryNumber of Subjects With HZ Related Complications, by Complication Type

Complication types included HZ vasculitis, Disseminated Disease, Ophtalmic Disease, Neurologic Disease, Visceral Disease and Stroke. This Outcome Measure was only assessed participants with confirmed HZ.

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Number of Subjects With HZ Related Complications, by Complication Type
ParticipantsGSK1437173A 50-59 YOA GroupGSK1437173A 60-69 YOA GroupGSK1437173A Over 70 YOA GroupGSK1437173A Overall Ages GroupPlacebo 50-59 YOA GroupPlacebo 60-69 YOA GroupPlacebo Over 70 YOA GroupPlacebo Overall Ages Group
At least one complication00001326
HZ vasculitis00000101
Disseminated Disease00001124
Ophtalmic Disease00000101
Neurologic Disease00000000
Visceral Disease00000000
Stroke00000000
SecondaryDistribution of Pain Medication Associated With HZ

The distribution of pain medication included 1 to 3 or more separate medications. This Outcome Measure was only assessed on participants with confirmed HZ.

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Distribution of Pain Medication Associated With HZ
ParticipantsGSK1437173A 50-59 YOA GroupGSK1437173A 60-69 YOA GroupGSK1437173A Over 70 YOA GroupGSK1437173A Overall Ages GroupPlacebo 50-59 YOA GroupPlacebo 60-69 YOA GroupPlacebo Over 70 YOA GroupPlacebo Overall Ages Group
At least one pain medication3216826345190
1 pain medication only110230231467
2 pain medications only11022619954
3 pain medications or more101226212269
SecondaryNumber of Days of Pain Medication Associated With HZ

The analysis was performed on subjects with a confirmed HZ episode

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Mean · Days
Number of Days of Pain Medication Associated With HZ
DaysGSK1437173A 50-59 YOA GroupGSK1437173A 60-69 YOA GroupGSK1437173A Over 70 YOA GroupGSK1437173A Overall Ages GroupPlacebo 50-59 YOA GroupPlacebo 60-69 YOA GroupPlacebo Over 70 YOA GroupPlacebo Overall Ages Group
Number of Days of Pain Medication Associated With HZ17.3 ± 14.520.5 ± 16.363.0 ± 0.026.0 ± 21.649.2 ± 121.574.3 ± 166.3127.7 ± 266.976.1 ± 181.5
SecondaryNumber of Subjects With Any and Grade 3 Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = Significant pain at rest that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed.

Time frame:
During the 7-day (Days 0-6) post-vaccination period
Reported as:
Count of participants · Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
ParticipantsGSK1437173A GroupPlacebo Group
Any Pain, Dose 13120352
Grade 3 Pain, Dose 11596
Any Redness, Dose 1122540
Grade 3 Redness, Dose 1820
Any Swelling, Dose 181031
Grade 3 Swelling, Dose 1280
Any Pain, Dose 22807258
Grade 3 Pain, Dose 218510
Any Redness, Dose 2115124
Grade 3 Redness, Dose 2560
Any Swelling, Dose 276217
Grade 3 Swelling, Dose 2180
Any Pain, Overall3463490
Grade 3 Pain, Overall29316
Any Redness, Overall166559
Grade 3 Redness, Overall1210
Any Swelling, Overall115346
Grade 3 Swelling, Overall430
SecondaryNumber of Subjects With Any, Grade 3 and Related Solicited General Symptoms

Assessed solicited general symptoms were fatigue, GI (gastrointestinal) symptoms (included nausea, vomiting, diarrhoea and/or abdominal pain), fever \[defined as oral, axillary, rectal or tympanic temperature equal to or above 37.5 degrees Celsius (°C)\], headache, myalgia, shivering and sweating. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = temperature\> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

Time frame:
Within the 7-day (Days 0-6) post-vaccination period
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
ParticipantsGSK1437173A GroupPlacebo Group
Any Fatigue, Dose 11395531
Grade 3 Fatigue, Dose 110929
Related fatigue, Dose 11153355
Any GI symptoms, Dose 1465263
Grade 3 GI symptoms, Dose 13012
Related GI symptoms, Dose 1317141
Any Headache, Dose 11112511
Grade 3 Headache, Dose 16720
Related Headache, Dose 1891341
Any Myalgia, Dose 11446377
Grade 3 Myalgia, Dose 110421
Related Myalgia, Dose 11231265
Any Shivering, Dose 1632166
Grade 3 Shivering, Dose 1693
Related Shivering, Dose 1539104
Any Temperature, Dose 150065
Grade 3 Temperature, Dose 171
Related Temperature, Dose 142038
Any Fatigue, Dose 21456379
Grade 3 Fatigue, Dose 215718
Related fatigue, Dose 21270279
Any GI symptoms, Dose 2495183
Grade 3 GI symptoms, Dose 23314
Related GI symptoms, Dose 239291
Any Headache, Dose 21249340
Grade 3 Headache, Dose 210513
Related Headache, Dose 21107219
Any Myalgia, Dose 21474274
Grade 3 Myalgia, Dose 216013
Related Myalgia, Dose 21314197
Any Shivering, Dose 2947128
Grade 3 Shivering, Dose 21399
Related Shivering, Dose 283888
Any Temperature, Dose 264572
Grade 3 Temperature, Dose 285
Related Temperature, Dose 257140
Any Fatigue, Overall2006728
Grade 3 Fatigue, Overall24146
Related fatigue, Overall1724522
Any GI symptoms, Overall787386
Grade 3 GI symptoms, Overall6125
Related GI symptoms, Overall591206
Any Headache, Overall1714700
Grade 3 Headache, Overall15730
Related Headache, Overall1470469
Any Myalgia, Overall2023529
Grade 3 Myalgia, Overall23631
Related Myalgia, Overall1791390
Any Shivering, Overall1232259
Grade 3 Shivering, Overall19211
Related Shivering, Overall1082177
Any Temperature, Overall940132
Grade 3 Temperature, Overall146
Related Temperature, Overall81378
SecondaryNumber of Subjects With Any and Grade 3 Symptoms (Solicited and Unsolicited)

Number of subjects with any and grade 3 solicited and unsolicited symptoms were tabulated

Time frame:
Within the 7-day (Days 0-6) post-vaccination period
Reported as:
Count of participants · Participants
Number of Subjects With Any and Grade 3 Symptoms (Solicited and Unsolicited)
ParticipantsGSK1437173A GroupPlacebo Group
Any solicited or unsolicited symptoms37661691
Grade 3 solicited or unsolicited symptoms759145
SecondaryNumber of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)

Occurrence and relationship to vaccination of any potential immune-mediated diseases (pIMDs) in all subjects

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)
ParticipantsGSK1437173A GroupPlacebo Group
Any pIMDs87105
Related pIMDs812
SecondaryNumber of Subjects With AEs With Any and Related Medically Attended Visit

Occurrence and relationship to vaccination of medically attended visits (defined as hospitalizations, emergency room visits or visits to or from medical personnel), other than routine health care visits in all subjects.

Time frame:
From Month 0 to Month 8 post-vaccination
Reported as:
Count of participants · Participants
Number of Subjects With AEs With Any and Related Medically Attended Visit
ParticipantsGSK1437173A GroupPlacebo Group
Any medically attended visits29523072
Related medically attended visits14260
SecondaryNumber of Subjects With Unsolicited Adverse Events (AEs)

Occurrence, intensity and relationship to vaccination of unsolicited AEs, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification in all subjects An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

Time frame:
Within 30 days (Days 0 - 29) after each vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Unsolicited Adverse Events (AEs)
ParticipantsGSK1437173A GroupPlacebo Group
Any unsolicited AEs35342426
Grade 3 unsolicited AEs609298
Related unsolicited AEs2199439
SecondaryNumber of Subjects With Serious Adverse Events (SAEs)

Occurrence and relationship to vaccination of all SAEs in all subjects. Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
Within the 30-day (Days 0-29) post-vaccination period, up to Month 14 and up to study end (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs)
ParticipantsGSK1437173A GroupPlacebo Group
Any SAEs (up to Day 30)8897
Related SAEs (up to Day 30)13
Any SAEs (up to Month 14)594590
Related SAEs (up to Month 14)36
Any SAEs (up to study end)727731
Related SAEs (up to study end)37
SecondaryNumber of Subjects With SAEs Related to Study Participation or to a Concurrent GSK Medication/Vaccine

The number of subjects with SAEs related to study participation or to a concurrent GSK medication/vaccine were tabulated

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Number of Subjects With SAEs Related to Study Participation or to a Concurrent GSK Medication/Vaccine
ParticipantsGSK1437173A GroupPlacebo Group
Number of Subjects With SAEs Related to Study Participation or to a Concurrent GSK Medication/Vaccine4325
SecondaryNumber of Subjects With Fatal SAEs

Number of subjects with fatal SAEs during the entire study period were tabulated

Time frame:
During the entire study period (3 to 5 years following day 0)
Reported as:
Count of participants · Participants
Number of Subjects With Fatal SAEs
ParticipantsGSK1437173A GroupPlacebo Group
Number of Subjects With Fatal SAEs208221

Adverse events

Collected over Solicited symptoms: within 7 days post-vaccination Unsolicited AEs: within 30 days post vaccination SAEs: during the entire study period (3 to 5 year period following Day 0). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK1437173A Group11/7,695 (0.1%)727/7,695 (9.4%)5,586/7,695 (72.6%)
Placebo Group15/7,710 (0.2%)731/7,710 (9.5%)1,893/7,710 (24.6%)
Most frequent serious events
Showing 10 of 782
Most frequent serious events
EventGSK1437173A GroupPlacebo Group
PneumoniaInfections and infestations40/769526/7710
Myocardial infarctionCardiac disorders28/769527/7710
Cardiac failureCardiac disorders20/769524/7710
Atrial fibrillationCardiac disorders19/76956/7710
Cerebrovascular accidentNervous system disorders19/769512/7710
Acute myocardial infarctionCardiac disorders8/769519/7710
Coronary artery diseaseCardiac disorders11/769517/7710
DeathGeneral disorders11/769515/7710
Cardiac failure congestiveCardiac disorders14/769510/7710
SepsisInfections and infestations7/769513/7710
Most frequent other events
Showing 10 of 12
Most frequent other events
EventGSK1437173A GroupPlacebo Group
PainGeneral disorders3575/7695505/7710
MyalgiaMusculoskeletal and connective tissue disorders2277/7695571/7710
FatigueGeneral disorders2211/7695770/7710
HeadacheNervous system disorders2167/7695929/7710
ErythemaSkin and subcutaneous tissue disorders1690/769569/7710
PyrexiaGeneral disorders1498/7695168/7710
ChillsGeneral disorders1464/7695276/7710
Injection site painGeneral disorders1390/7695104/7710
SwellingGeneral disorders1154/769546/7710
Gastrointestinal disorderGastrointestinal disorders792/7695389/7710

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GSK1437173A GroupPlacebo GroupTotal
Mean62.4 ± 9.062.3 ± 9.062.35 ± 9.0
Age, Customized
Age, Customized(Participants)GSK1437173A GroupPlacebo GroupTotal
50 - 59 YOA364436427286
60 - 69 YOA224322454488
>= 70 YOA180818233631
Sex: Female, Male
Sex: Female, Male(Participants)GSK1437173A GroupPlacebo GroupTotal
Female470947119420
Male298629995985
08

Study locations

274 sites
  • GSK Investigational Site
    Mesa, Arizona 85213, United States
  • GSK Investigational Site
    Phoenix, Arizona 85018, United States
  • GSK Investigational Site
    Phoenix, Arizona 85020, United States
  • GSK Investigational Site
    Phoenix, Arizona 85050, United States
  • GSK Investigational Site
    Tucson, Arizona 85704, United States
  • GSK Investigational Site
    Spring Valley, California 91978, United States
  • GSK Investigational Site
    Vista, California 92083, United States
  • GSK Investigational Site
    Clearwater, Florida 33761, United States
  • GSK Investigational Site
    DeLand, Florida 32720, United States
  • GSK Investigational Site
    Jacksonville, Florida 32205, United States
  • GSK Investigational Site
    Jacksonville, Florida 32216, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33409, United States
  • GSK Investigational Site
    Meridian, Idaho 83642, United States
  • GSK Investigational Site
    Overland Park, Kansas 66212, United States
  • GSK Investigational Site
    Wichita, Kansas 67207, United States
  • GSK Investigational Site
    Baltimore, Maryland 21209, United States
  • GSK Investigational Site
    Columbia, Maryland 21045, United States
  • GSK Investigational Site
    Kansas City, Missouri 64114, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89104, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89119, United States
  • GSK Investigational Site
    Edison, New Jersey 08817, United States
  • GSK Investigational Site
    Somers Point, New Jersey 08244, United States
  • GSK Investigational Site
    Cary, North Carolina 27518, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28209, United States
  • GSK Investigational Site
    Hickory, North Carolina 28602, United States
  • GSK Investigational Site
    Salisbury, North Carolina 28144, United States
  • GSK Investigational Site
    Wilmington, North Carolina 28401, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • GSK Investigational Site
    Cleveland, Ohio 44122, United States
  • GSK Investigational Site
    Wadsworth, Ohio 44281, United States
  • GSK Investigational Site
    Carnegie, Pennsylvania 15106, United States
  • GSK Investigational Site
    Pleasant Hills, Pennsylvania 15236, United States
  • GSK Investigational Site
    Uniontown, Pennsylvania 15401, United States
  • GSK Investigational Site
    Greer, South Carolina 29650, United States
  • GSK Investigational Site
    Mount Pleasant, South Carolina 29464, United States
  • GSK Investigational Site
    Bristol, Tennessee 37620, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Murray, Utah 84123, United States
  • GSK Investigational Site
    Arlington, Virginia 22203, United States
  • GSK Investigational Site
    Norfolk, Virginia 23502, United States
  • GSK Investigational Site
    Richmond, Virginia 23294, United States
  • GSK Investigational Site
    Winchester, Virginia 22601, United States
  • GSK Investigational Site
    Renton, Washington 98057, United States
  • GSK Investigational Site
    Glebe, New South Wales 2037, Australia
  • GSK Investigational Site
    Maroubra, New South Wales 2035, Australia
  • GSK Investigational Site
    Umina, New South Wales 2257, Australia
  • GSK Investigational Site
    Westmead, New South Wales 2145, Australia
  • GSK Investigational Site
    Wollongong, New South Wales 2522, Australia
  • GSK Investigational Site
    Sherwood, Queensland 4075, Australia
  • GSK Investigational Site
    Geelong, Victoria 3220, Australia
  • GSK Investigational Site
    Ivanhoe, Victoria 3079, Australia
  • GSK Investigational Site
    Belo Horizonte, Minas Gerais 30150-221, Brazil
  • GSK Investigational Site
    Belo Horizonte, Minas Gerais 30150-, Brazil
  • GSK Investigational Site
    Curitiba/Paraná, Paraná 80810-050, Brazil
  • GSK Investigational Site
    Curitiba/Paraná, Paraná 80810-, Brazil
  • GSK Investigational Site
    Porto Alegre, Rio Grande Do Sul 90035003, Brazil
  • GSK Investigational Site
    Porto Alegre, Rio Grande Do Sul 900350, Brazil
  • GSK Investigational Site
    Curitiba/PR, 80240-280, Brazil
  • GSK Investigational Site
    Curitiba/PR, 80240-, Brazil
  • GSK Investigational Site
    São Paulo, 04038 002, Brazil
  • GSK Investigational Site
    São Paulo, 04038, Brazil
  • GSK Investigational Site
    São Paulo, 04266-010, Brazil
  • GSK Investigational Site
    São Paulo, 04266-, Brazil
  • GSK Investigational Site
    São Paulo, 04312903, Brazil
  • GSK Investigational Site
    São Paulo, 043129, Brazil
  • GSK Investigational Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • GSK Investigational Site
    Vancouver, British Columbia V5Z 1M, Canada
  • GSK Investigational Site
    Victoria, British Columbia V8V 3P9, Canada
  • GSK Investigational Site
    Victoria, British Columbia V8V 3P, Canada
  • GSK Investigational Site
    Bay Roberts, Newfoundland and Labrador A0A 1G0, Canada
  • GSK Investigational Site
    Bay Roberts, Newfoundland and Labrador A0A 1G, Canada
  • GSK Investigational Site
    Halifax, Nova Scotia B3K 6R8, Canada
  • GSK Investigational Site
    Halifax, Nova Scotia B3K 6R, Canada
  • GSK Investigational Site
    Truro, Nova Scotia B2N 1L2, Canada
  • GSK Investigational Site
    Truro, Nova Scotia B2N 1L, Canada
  • GSK Investigational Site
    Toronto, Ontario M4S 1Y2, Canada
  • GSK Investigational Site
    Toronto, Ontario M4S 1Y, Canada
  • GSK Investigational Site
    Toronto, Ontario M9W 4L6, Canada
  • GSK Investigational Site
    Toronto, Ontario M9W 4L, Canada
  • GSK Investigational Site
    Woodstock, Ontario N4S 5P5, Canada
  • GSK Investigational Site
    Woodstock, Ontario N4S 5P, Canada
  • GSK Investigational Site
    Gatineau, Quebec J8Y 6S8, Canada
  • GSK Investigational Site
    Gatineau, Quebec J8Y 6S, Canada
  • GSK Investigational Site
    Mirabel, Quebec J7J 2K8, Canada
  • GSK Investigational Site
    Mirabel, Quebec J7J 2K, Canada
  • GSK Investigational Site
    Pointe-Claire, Quebec H9R 4S3, Canada
  • GSK Investigational Site
    Pointe-Claire, Quebec H9R 4S, Canada
  • GSK Investigational Site
    Quebec City, Quebec G1E 7G9, Canada
  • GSK Investigational Site
    Quebec City, Quebec G1E 7G, Canada
  • GSK Investigational Site
    Sherbrooke, Quebec J1H 2G2, Canada
  • GSK Investigational Site
    Sherbrooke, Quebec J1H 2G, Canada
  • GSK Investigational Site
    Trois Rivières, Quebec G8T 7A1, Canada
  • GSK Investigational Site
    Trois Rivières, Quebec G8T 7A, Canada
  • GSK Investigational Site
    Quebec, G1W 4R4, Canada
  • GSK Investigational Site
    Quebec, G1W 4R, Canada
  • GSK Investigational Site
    Brno, 662 10, Czechia
  • GSK Investigational Site
    Ceske Budejovice, 370 04, Czechia
  • GSK Investigational Site
    Hradec Kralove, 500 01, Czechia
  • GSK Investigational Site
    Tallinn, 13619, Estonia
  • GSK Investigational Site
    Tartu, 50106, Estonia

Showing the first 100 of 274 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barbera J, Vanden Abeele C, Vesikari T, Watanabe D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF, Campora L, de Looze F, Downey HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo L, Smetana J, Weckx L, Yeo W, Heineman TC; ZOE-70 Study Group. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med. 2016 Sep 15;375(11):1019-32. doi: 10.1056/NEJMoa1603800. PubMed 27626517 ↗
  • Cunningham AL, Heineman TC, Lal H, Godeaux O, Chlibek R, Hwang SJ, McElhaney JE, Vesikari T, Andrews C, Choi WS, Esen M, Ikematsu H, Choma MK, Pauksens K, Ravault S, Salaun B, Schwarz TF, Smetana J, Abeele CV, Van den Steen P, Vastiau I, Weckx LY, Levin MJ; ZOE-50/70 Study Group. Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older. J Infect Dis. 2018 May 5;217(11):1750-1760. doi: 10.1093/infdis/jiy095. PubMed 29529222 ↗
  • Ikematsu H et al. (2018) Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi. 92(2):103-114.
  • Kovac M, Lal H, Cunningham AL, Levin MJ, Johnson RW, Campora L, Volpi A, Heineman TC; ZOE-50/70 Study Group. Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials. Vaccine. 2018 Mar 14;36(12):1537-1541. doi: 10.1016/j.vaccine.2018.02.029. Epub 2018 Feb 17. PubMed 29463421 ↗
  • Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barbera J, Vesikari T, Watanabe D, Weckx L, Zahaf T, Heineman TC; ZOE-50 Study Group. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May 28;372(22):2087-96. doi: 10.1056/NEJMoa1501184. Epub 2015 Apr 28. PubMed 25916341 ↗
  • Carryn S, Cheuvart B, Povey M, Dagnew AF, Harpaz R, van der Most R, Casabona G. No Consistent Evidence of Decreased Exposure to Varicella-Zoster Virus Among Older Adults in Countries with Universal Varicella Vaccination. J Infect Dis. 2022 Feb 1;225(3):413-421. doi: 10.1093/infdis/jiab500. PubMed 34609490 ↗
  • Kim JH, Diaz-Decaro J, Jiang N, Hwang SJ, Choo EJ, Co M, Hastie A, Hui DSC, Irimajiri J, Lee J, Leung EM, Tang H, Tsuru T, Watson P, Wu Z, Yu CJ, Yuan Y, Zahaf T, Cunningham AL, Schuind A. The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults >/= 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials. Hum Vaccin Immunother. 2021 Jul 3;17(7):2050-2057. doi: 10.1080/21645515.2020.1859321. Epub 2021 Feb 19. PubMed 33606577 ↗
  • Dagnew AF, Rausch D, Herve C, Zahaf T, Levin MJ, Schuind A; ZOE-50/70 study group. Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials. Rheumatology (Oxford). 2021 Mar 2;60(3):1226-1233. doi: 10.1093/rheumatology/keaa424. PubMed 32910152 ↗
  • Colindres R, Wascotte V, Brecx A, Clarke C, Herve C, Kim JH, Levin MJ, Oostvogels L, Zahaf T, Schuind A, Cunningham AL. Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials. Hum Vaccin Immunother. 2020 Nov 1;16(11):2628-2633. doi: 10.1080/21645515.2020.1741312. Epub 2020 Apr 29. PubMed 32347767 ↗
  • Willer DO, Oostvogels L, Cunningham AL, Gervais P, Gorfinkel I, Hyung Kim J, Talarico C, Wascotte V, Zahaf T, Colindres R, Schuind A; ZOE 50/70 study groups. Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials. Vaccine. 2019 Oct 8;37(43):6262-6267. doi: 10.1016/j.vaccine.2019.09.028. Epub 2019 Sep 16. PubMed 31537443 ↗
  • Lopez-Fauqued M, Campora L, Delannois F, El Idrissi M, Oostvogels L, De Looze FJ, Diez-Domingo J, Heineman TC, Lal H, McElhaney JE, McNeil SA, Yeo W, Tavares-Da-Silva F; ZOE-50/70 Study Group. Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials. Vaccine. 2019 Apr 24;37(18):2482-2493. doi: 10.1016/j.vaccine.2019.03.043. Epub 2019 Mar 29. PubMed 30935742 ↗
  • Curran D, Oostvogels L, Heineman T, Matthews S, McElhaney J, McNeil S, Diez-Domingo J, Lal H, Andrews C, Athan E, Berglund J, Campora L, de Looze F, Korhonen T, Leung E, Levin M, Volpi A, Johnson RW; ZOE-50/70 Study Group. Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older. J Gerontol A Biol Sci Med Sci. 2019 Jul 12;74(8):1231-1238. doi: 10.1093/gerona/gly150. PubMed 29955836 ↗

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2010 to primary completion in May 2014, 45 months.

Results were first posted in May 2017, 2 years 11 months after primary completion. A results delay was requested in Aug 2013.

Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 45 months is above that.

Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2010
First posted
Jul 19, 2010
StartActual
Aug 2, 2010
Primary completionActual
May 9, 2014
CompletionActual
Jul 27, 2015
Results delay requested
Aug 22, 2013
Results first posted
May 1, 2017
Last update
Feb 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01165177
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 19, 2010
Start date
Aug 2, 2010
Primary completion
May 9, 2014
Completion
Jul 27, 2015
Results posted
May 1, 2017
Last update
Feb 10, 2021

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Shingrix

Start the discussion